Clinical Trials
15 trialsNCT03093116 2026-05-27
TRIDENT-1
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT07164313 2026-05-07
A Study of ZW251 in Participants With Advanced Solid Tumors
Zymeworks BC Inc.
Phase 1 Recruiting
NCT05394675 2026-03-20
A Study of DS-9606a in Patients With Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Terminated
NCT06276491 2026-03-17
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Xencor, Inc.
Phase 1 Recruiting
NCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT06940804 2025-07-02
AVENTURINE
BioNTech SE
Phase 2 Withdrawn
NCT03037385 2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2 Completed
NCT05592743 2024-11-05
Vorasidenib Expanded Access Program
Servier
Approved for marketing
NCT06363201 2024-04-12
Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumours
Catalysis SL
Phase NA Unknown
NCT02571036 2023-12-13
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
Phase 1 Completed
NCT04697446 2021-08-10
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
Blueprint Medicines Corporation
Unknown
NCT02300987 2020-10-26
A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression
Novartis
Phase 2 Completed
NCT02197169 2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1 Completed
NCT00753415 2015-03-17
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00611962 2008-02-11
Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin
Sanofi
Phase 2 Completed